Extrait

To evaluate the feasibility, safety and tolerability of this treatment regimen, and to determine acceptable 90-Y dose and gemcitabine dosing for use with this approach.

Critère d'inclusion

• This is a phase Ib, open-label, dose exploration study of 90-Y-hPAM4 administered as one or more treatment cycles of fractionated radioimmunotherapy in combination with radiosensitizing gemcitabine as front line therapy for patients with Stage III (unresectable locally advanced) or Stage IV (metastatic) pancreatic cancer, including patients who may have undergone surgery bu had incomplete resections

Liens

• euctr
• ictrp